• Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix, Arizona, last year. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. | AP
    Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix, Arizona, last year. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. | AP

  • Reuters

  • SHARE

BANGALORE, INDIA – Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer’s treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decline of patients.

The drugmaker’s shares soared 27 percent in New York trading, recouping almost all of the $18 billion it lost when it said in March it was abandoning the two studies. Shares in Eisai Co., Biogen’s Japanese partner in the drug, were quoted up 18 percent to the daily limit high of ¥6,534 in Tokyo trading.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)

, , , , , ,